Navigation Links
Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
Date:10/23/2007

LONDON, Oct. 23 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced the initiation of a Phase I tolerance study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).

The randomized, placebo-controlled, double blind clinical trial is the first of two modules focusing on safety for Morria's first human study in AR. MRX-4 is nasally administered as a single dose either with or without an allergen challenge to determine tolerance. Results are expected by the end of the fourth quarter of 2007.

"We are excited to be taking this significant step toward introducing a potentially safer, more effective and more affordable treatment option to the multibillion-dollar AR market," said Yuval Cohen Ph.D., President of Morria.

"There is a real and urgent need for novel, non-steroidal treatments for inflammatory diseases such as allergic rhinitis. Morria's drug platform could potentially offer such an alternative," said Peter Barnes, a professor at the National Heart & Lung Institute at Imperial College in London and Morria scientific advisory board member.

ABOUT ALLERGIC RHINITIS

Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of nearly $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals known as multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known but previously elusive anti-inflammatory drug target. At the same time, they also protect cells and tissues against inflammatory damage. Morria is determined to become a pivotal player in the $20 billion anti-inflammatory drug market by developing and commercializing novel drugs for acute pulmonary and gastrointestinal inflammatory diseases. For more information, please visit http://www.morria.com.

This release is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order -- Persons in the business of disseminating information.

UK CONTACT: Yuval Cohen, President

53 Davies Street, London, W1K 5JH, United Kingdom

Tel: +44 (0) 207 152 6341 or info@morria.com

US CONTACT: Meghan Feeks

Richard Lewis Communications, Inc.

35 West 35 St., Suite 505, New York, NY 10001

Tel: +1 212-827-0020 or mfeeks@rlcinc.com


'/>"/>
SOURCE Morria Biopharmaceuticals Plc
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
3. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
6. Malvern initiates European user group meetings for chemical imaging
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... WELLESLEY, Massachusetts , May 26, 2016 ... sequencing (NGS) has matured into an essential life science ... research and development applications. BCC Research reveals in its ... of a second growth phase, one powered by a ... applied fields.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ...
(Date:5/25/2016)... IRVINE, Calif. , May 25, 2016 /PRNewswire/ ... of testing for their new reference materials that ... workflows from sample collection to analyses. The rapid ... the demand for researchers to have standard methods ... data being generated. Biases inherently exist at every ...
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 26, 2016 , ... On Memorial Day, Hope For Heroes and ... military battle for the country. The nonprofit Hope For Heroes partnered with the ... empower independence for disabled military veterans, as well as police, firemen, and EMS professionals ...
(Date:5/26/2016)... ... 26, 2016 , ... There are nearly 14.5 million people living with and ... On Sunday, June 5, 2016, communities around the world will gather to recognize these ... National Cancer Survivors Day® is an annual worldwide Celebration of Life that is held ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will ... Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public ... Retina Group of New York , is a Board Certified ophthalmologist who ...
(Date:5/26/2016)... R.I. (PRWEB) , ... May 26, 2016 , ... Memorial ... That’s why Amica Insurance is sharing tips to make sure your family ... estimate from the National Safety Council, there may be 439 deaths and an additional ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Lung Institute has partnered ... cessation class starting June 6 at their clinic in downtown Tampa. The class is ... the Lung Institute has created a free downloadable 4 Week Smoking Cessation Guide ...
Breaking Medicine News(10 mins):